Ryota Sakurai1,2,3, Manuel Montero-Odasso1,2,4. 1. Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Canada. 2. Schulich School of Medicine and Dentistry, Department of Medicine, Division of Geriatric Medicine, University of Western Ontario, London, Canada. 3. Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 4. Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada.
Abstract
BACKGROUND: The apolipoprotein E polymorphism ε4 allele (ApoE4) and gait impairment are both known risk factors for developing cognitive decline and dementia. However, it is unclear the interrelationship between these factors, particularly among older adults with mild cognitive impairment (MCI) who are considered as prodromal for Alzheimer's disease. This study aimed to determine whether ApoE4 carrier individuals with MCI may experience greater impairment in gait performance. METHODS: Fifty-six older adults with MCI from the "Gait and Brain Study" who were identified as either ApoE4 carriers (n = 20) or non-ApoE4 carriers (n = 36) with 1 year of follow-up were included. Gait variability, the main outcome variable, was assessed as stride time variability with an electronic walkway. Additional gait variables and cognitive performance (mini-mental state examination [MMSE] and Montreal Cognitive Assessment [MoCA]) were also recorded. Covariates included age, sex, education level, body mass index, and number of comorbidities. RESULTS: Baseline characteristics were similar for both groups. Repeated measures analysis of covariance showed that gait stride time and stride length variabilities significantly increased in ApoE4 carriers but was maintained in the non-ApoE4 carriers. Similarly, ApoE4 carriers showed greater decrease in MMSE score at follow-up. CONCLUSIONS: In this sample of older adults with MCI, the presence of at least one copy of ApoE4 was associated with the development of both increased gait variability and cognitive decline during 1 year of follow-up. ApoE4 genotype might be considered as a potential mediator of decline in mobility function in MCI; future studies with larger samples are needed to confirm our preliminary findings.
BACKGROUND: The apolipoprotein E polymorphism ε4 allele (ApoE4) and gait impairment are both known risk factors for developing cognitive decline and dementia. However, it is unclear the interrelationship between these factors, particularly among older adults with mild cognitive impairment (MCI) who are considered as prodromal for Alzheimer's disease. This study aimed to determine whether ApoE4 carrier individuals with MCI may experience greater impairment in gait performance. METHODS: Fifty-six older adults with MCI from the "Gait and Brain Study" who were identified as either ApoE4 carriers (n = 20) or non-ApoE4 carriers (n = 36) with 1 year of follow-up were included. Gait variability, the main outcome variable, was assessed as stride time variability with an electronic walkway. Additional gait variables and cognitive performance (mini-mental state examination [MMSE] and Montreal Cognitive Assessment [MoCA]) were also recorded. Covariates included age, sex, education level, body mass index, and number of comorbidities. RESULTS: Baseline characteristics were similar for both groups. Repeated measures analysis of covariance showed that gait stride time and stride length variabilities significantly increased in ApoE4 carriers but was maintained in the non-ApoE4 carriers. Similarly, ApoE4 carriers showed greater decrease in MMSE score at follow-up. CONCLUSIONS: In this sample of older adults with MCI, the presence of at least one copy of ApoE4 was associated with the development of both increased gait variability and cognitive decline during 1 year of follow-up. ApoE4 genotype might be considered as a potential mediator of decline in mobility function in MCI; future studies with larger samples are needed to confirm our preliminary findings.
Authors: Aron S Buchman; Patricia A Boyle; Robert S Wilson; Todd L Beck; Jeremiah F Kelly; David A Bennett Journal: Alzheimer Dis Assoc Disord Date: 2009 Jan-Mar Impact factor: 2.703
Authors: Manuel M Montero-Odasso; Brittany Barnes; Mark Speechley; Susan W Muir Hunter; Timothy J Doherty; Gustavo Duque; Karen Gopaul; Luciano A Sposato; Alvaro Casas-Herrero; Michael J Borrie; Richard Camicioli; Jennie L Wells Journal: J Gerontol A Biol Sci Med Sci Date: 2016-03-16 Impact factor: 6.053
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Manuel Montero-Odasso; Afua Oteng-Amoako; Mark Speechley; Karen Gopaul; Olivier Beauchet; Cedric Annweiler; Susan W Muir-Hunter Journal: J Gerontol A Biol Sci Med Sci Date: 2014-09-02 Impact factor: 6.053
Authors: Douglas N Martini; Rosie Morris; Valerie E Kelly; Amie Hiller; Kathryn A Chung; Shu-Ching Hu; Cyrus P Zabetian; John Oakley; Kathleen Poston; Ignacio F Mata; Karen L Edwards; Jodi A Lapidus; Thomas J Grabowski; Thomas J Montine; Joseph F Quinn; Fay Horak Journal: Front Neurol Date: 2020-09-04 Impact factor: 4.003